Samsung Bioepis Submits a Biosimilar Candidate, to the European Medicines Agency

14/03/2015 - 2 minutes

Samsung Bioepis announced their submission to the to the European Medicines Agency (EMA) for SB2, its Remicade (Infliximab) biosimilar candidate. This is the second biosimilar candidate Marketing Authorization Application (MAA) that Samsung Bioepis has submitted to the EMA.

The MAA is based on results from an extensive head-to-head preclinical data package comparing SB2 to the originator, a head-to-head phase I study in healthy volunteers, and a robust head-to-head phase III equivalence trial in patients with moderate-to-severe rheumatoid arthritis (RA). In Europe, Remicade is indicated for the treatment of rheumatic arthritis, adult Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, ankylosing spondylitis and psoriasis. If authorized by the EMA, SB2 could be available for use in all of the same indications as Remicade. If authorized by the EMA, SB2 will be commercialized in Europe by Biogen Idec.

If this MAA is approved by EMA, Samsung Bioepis will provide rheumatoid arthritis patients inEurope with an important new treatment option,” said Christopher Hansung Ko,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!